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ABSTRACT
Objective: This research aims to evaluate the histopathological changes after pretreatment with resatorvid against methotrexate induced-liver injury.
Methods: 28 male albino-wistar rats divided into random 4 groups (7 rats in each). Control group: Rats left untreated. Vehicle pre-treated group: Rats 
were administered dimethyl sulfoxide (DMSO) followed by methotrexate (MTX). Methotrexate treated group: Rats left untreated then administered 
MTX. Resatorvid pre-treated group: Rats were administered resatorvid followed by MTX.  24 h after the end of treatment, the animals were sacrificed. 
Liver tissue samples dissected out immediately and fixed in 10% formalin. The traditional procedures (paraffin-embedded method) was used to 
prepare liver tissue for microscopic evaluation by none alcoholic fatty liver disease (NAFLD) Activity Score Components.
Results: Liver tissue sections of MTX-treated group show moderate-to-severe steatosis of hepatic cells and micro- and macro- hepatocellular fatty 
degeneration and  giant fatty cysts with chronic inflammatory cells infiltration. While liver tissue sections of the resatorvid pre-treated group show 
moderate hepatic cellular fatty degeneration, with a decreased number of fatty cysts chains and the inflammation disappeared.
Conclusion: Resatorvid hepatoprotective effect against MTX-induced injury was promising throughout resolving the accompanying inflammation 
and partial restoring histopathological fatty alterations.
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INTRODUCTION
Resatorvid is a selective inhibitor of toll-like receptor 4 (TLR4) 
signal transduction pathway. It interferes with the intracellular toll/
interleukin-receptor (TIR) domain adaptor molecule interaction [1,2]. 
Its structure (Fig. 1) with α-β unsaturated carbonyl group would allow 
it to act as Michael acceptor, via its cyclohexene ring which covalently 
bonds the nucleophilic cysteine 747 residue (Cys747) located at TIR 
domain that is necessary for TLR4 homodimeraization phase [3,4,5].
TLR4 is a member of the pattern recognition receptor (PRR), the 
family that are widely expressed by hepatic, parenchymal and/non-
parenchymal cells as well as activate hepatic tissue inflammatory 
response [6,7]. Hepatocytes are the main site for PRR expression 
despite their weak response to TLR4 ligand. Hepatic kupffer cells 
(KCs), stellate cells (HSCs), and dendritic cells directly respond to TLR 
after their activation producing pro-inflammatory cytokines (CKs) 
that are the end product of TLRs pathways while playing an indefinite 
role in sinusoidal endothelial cells (SECs). TLRs are also expressed 
by lymphocytes [6-8]. Therefore, TLR4 is perhaps an attractive target 
for MTX-induced liver injury since MTX hepatotoxicity involves 
generation of free radicals (FR), oxidative stress and imbalance of 
cellular oxidant/antioxidant enzymes, these mechanisms lead to 
immune stimulation and production of proinflammatory CKs that 
may involve TLR4 induced inflammatory pathways [9-12].
Aim of the study
This research aims to evaluate the histopathological changes after pre-
treatment with resatorvid against methotrexate induced-liver injury in 
an albino-wistar rat model.
METHODS
Experimental design
A total of 28 male albino Wistar rats (aged 4–6 mo and weighed 
125–225 g) taken from Kut Technical Institute, University of Wasit, 
were maintained under non-specific pathogen-free conditions in wire-
meshed cages (7 rats in each cage) with ad libitum access to water and 
regular diet. The animals were kept under a constant temperature 24 ± 
3°C with 12:12 h light dark cycle [13-15]. Animal handling and housing 
have proceeded in accordance with the international guidelines for the 
care and use of laboratory animals of the National Research Council 
[13,14]. The ethical committee of the Pharmacology Department, 
College of Medicine, Mustansiriyah University, approved the experiment.
The animals were divided into random four groups (7 rats in each 
group) [14,16]: Control group: Rats kept on a regular diet and distilled 
water (D/W) throughout the 14 experimental d. Vehicle pre-treated 
group: Rats were administered intraperitoneal (i.p.) DMSO once for 
7 d [16,17], followed by 7 d of oral MTX 0.2 mg/kg/d once via rat oral 
gavage [14]. Methotrexate treated group: Rats were left untreated for 
7 d followed by 7 d of oral MTX 0.2 mg/kg/d once dependent on the 
adult dose for rheumatoid arthritis to stimulate model of induced liver 
injury [14]. Resatorvid pre-treated group: Animals were administered 
i.p. resatorvid 5 mg/kg/d once for 7 d [16], followed by 7 d of oral MTX 
0.2 mg/kg/d via rat oral gavage [14].
Chemical and drug preparation
Resatorvid (C15H17CIFNO4S - a white crystalline powder with DMSO 
solubility  of  ≥360  mg/mL  according  to  the  manufacturer)  was 
purchased from MedChemExpress, New Jersey, USA. It was dissolved in 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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DMSO and diluted with D/W to a final concentration of 17 mg/ml 1 h. 
Before it was administered i.p. according to rat’s weight [16,17]. MTX 
(C20H22N8O5 - 50 mg/ml injectable solution) was purchased from KOÇAK 
Farma, ÍSTANBUL, Turkey, diluted with D/W to a final concentration of 
0.333 mg/ml and administered via rat oral gavage according to rat weight 
[14]. DMSO: It was purchased as 99.5% solution from Central Drug House 
(P) Ltd., New Delhi, India. It was diluted with D/W to 8% w/v solution 
(the concentration used to dissolve resatorvid) and administered i.p. 
according to resatorvid protocol and rats weight [16,17].
Tissue sample collection and histopathological study
After 24 h of the end of the treatment, the rats were anaesthetized 
with Ketamine 91 mg/kg-Xylazine 9 mg/kg intramuscularly (I.M.), both 
were achieved from Alfasan woerden, Woerden, and Kepro, Deventer, 
Holland respectively [18,19]. A cut was done to rats’ abdomen using 
sharp scissor after animal scarification, and the liver was dissected out 
immediately. Liver tissue samples were fixed in containers with 30 ml 
of 10% formalin and stored in −28°C until their processing [16,20,21].
The traditional processing procedures of the paraffin-embedded method 
were used to prepare liver tissues for microscopic evaluation [22-24]. 
The procedures include liver tissues’ fixation in formalin 10%, cross-
sectional slicing, and tissue step-by-step dehydration in graduated 
ethanol series clearing the dehydrant using xylene [25,26]. Infiltration 
followed, tissue blocks embedding in paraffin and being placed in 
metal mold, labeled, discarding any paraffin excess, and allowing the 
paraffin to congeal at room temperature then placed in refrigerator. 
Steps continued with infiltration, tissue blocks embedding in paraffin 
and then placing them in a metal mould, labelling was done, followed 
by discarding paraffin excess, and allowing the paraffin to congeal at 
room temperature then transfer them to refrigerator [26]. Manual 
tissue sectioning utilizing microtome was done, followed by marking 
the cleansed slides with a diamond pen and adjustment of obtained 
tissue sections on slide surfaces by utilizing water bath at 45°C. Pulling 
the slides out to allow tissue section adherence to the slide surfaces. 
Drying the obtained slides in a storage box for 24 h. Tissue sections 
clearing and rehydration by xylene solution, alcohol and water 
performed for several times. Moving the slide box’s into a hot oven with 
65°C for 15 min followed by staining with hematoxylin and eosin (H & 
E) stains [21,26]. Finally, cover slides mounting using few drops of clear 
resin (a mixture of distyrene, a plasticizer, and xylene) to the bottom 
before setting the cover on the tissue section slowly. Finally allowing 
the obtained sections to dry on a slide warmer for 24 h [23].
Assessment of liver histopathology
Liver structure evaluation after methotrexate-induced injury done by 
professional pathologist utilizing a light microscope and assess the grade 
of the induced histopathological changes using histological scoring 
system for NAFLD [27]. This scoring system comprehends 3 main 
changes in the liver: Steatosis (S) range from 0-3, Lobular inflammation 
(L) range from 0-3, and Ballooning of hepatocytes (B) ranges from 0-2. 
The total scores represent the sum of all the hepatic changes according 
to the following equation and ranges from 0-8 (table 1) [27]. The digital 
photoshop software used to simplify the range of histopathological 
changes by X100 magnification.
Total NAFLD Activity Score (NAS) = S + L + B [27]
RESULTS
In this experiment, the resulted histopathological findings of the 
treated groups were graded as mild, moderate and severe findings. 
These findings were examined in 4 treatment groups each contain 7 
rats according to NAFLD component scoring system seen in Table 2.
Liver histopathological findings of the control group
control group liver tissue sections show normal hepatic cellular tissue, 
normal lobular rearrangement with total NAS (NAFLD activity scores) 
of 0 as seen in (Table 2) as well as (Figs. 2, 3,4 and 5).
Liver histopathological findings of the methotrexate-treated group
Liver tissue sections of this group showed moderate to severe steatosis 
of hepatic cells, degeneration of hepatic cell, micro- and macro-fatty 
vacuoles seen to join with each other forming giant fatty cysts with 
chronic inflammatory cells infiltration. Total NAS scores of 8 as seen in 
(Table 2) and in (Figs. 6, 7, 8 and 9).
Liver histopathological findings of the resatorvid pretreated group
liver tissues sections’ of this group show moderate hepatic cellular 
fatty degeneration, with a decreased number of fatty cysts chains and 
no inflammation observed as seen in Fig. 10, 11, 13 and 13. Total NAS 
scores obtained for this group of animals was 3 (Table 2).
DISCUSSION
Steatosis histopathologically characterized by the large fat vacuoles 
resulted from triglycerides (TG) deposition in the liver [28-30]. Their typical Fig. 1: Chemical structure of resatorvid [3]
Table 1: NAFLD activity score (NAS) components [27]
Item Score Extent (%) Definition and comment
Steatosis 0 <5 Refers to the amount of surface area involved by 
steatosis as evaluated on low-to-medium power 
examination (40X–100X); minimal steatosis (<5%) 
receives a score of 0 to avoid giving excess weight to 




Lobular inflammation 0 No foci Acidophil bodies are not included in this assessment nor 
is portal inflammation1 <2 foci/200x
2 2–4 foci/200x
3 >4 foci/200x
Hepatocyte ballooning 0 None The term “few” means rare but definite ballooned 
hepatocytes1 Few balloon cells
2 Many cells/prominent ballooning
NAFLD: Non-alcoholic fatty liver disease, NAS: NAFLD activity scores
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presentation involves microvesicular changes: the presence of small fat 
vacuoles (liposomes) surrounding the nucleus at the centre of hepatocytes 
due to mitochondrial injury [31,32]. The macrovesicular changes: these 
are the sequel follows microvesicular vacuoles that represent “small and 
large fat droplets” which occupies the whole hepatocyte and pushes the 
nucleus to the edge of the cell. These droplets can re-join together resulting 
in the development of irreversible fatty cysts which later appears empty 
vacuoles due to lipolysis [28,32,33], and Finally, Steatohepatitis refers to 
steatosis coexisting with hepatocellular ballooning, fibrosis, and lobular 
inflammation. It is also attributed to oxidative stress and mitochondrial 
loss of function  [10,31,32].
Chemotherapeutic drugs are the usual cause of multiple organ damage [34], 
especially those with self-renewing tissues. Since the liver is the main site 
for drug metabolism, so it is highly vulnerable to drug-induced liver injuries 
[11,28,31]. MTX is a classical chemotherapeutic and immunosuppressive 
Fig. 2: Liver section of normal control rats (no abnormality), 
H and E ×100
Fig. 5: Liver section of normal control rats (no abnormality), 
H and E ×100
Fig. 3: Liver section of normal control rats (no abnormality), 
H and E ×100
Fig. 4: Liver section of normal control rats (no abnormality), 
H and E ×100
Table 2: NAFLD activity score (NAS) components of the treatment groups
Score components Groups*
Control group** MTX group** Resatorvid
pre-treated group**
Steatosis
Score 0 3 2
Extent <5% >66% 33–66%
Lobular inflammation
Score 0 2 0
Extent None 2–4 foci/200x No inflammation
Ballooning degeneration
Score 0 2 1
Extent None Many Few cells
Total scores 0 8 3
NAS: NAFLD activity scores, * n=28 rats for the treatment groups, **n=7 rats for each group, ***Total score graded as severe (>= 5), moderate (3-4) and mild (< 3).
563
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 560-565
 Mohammad et al. 
Fig. 6: Liver section of methotrexate-treated rats (moderate-to-
severe steatosis) showing fatty degeneration of hepatic cells, 
microvesicular and macrovesicular fat vacuoles are shown joining 
each other and forming fatty cystic chains, H and E ×100
Fig. 7: Liver section of methotrexate-treated rats (moderate to 
severe steatosis) showing fatty degeneration of hepatic cells, 
micro-vesicular and macro-vesicular fat vacuoles are shown 
joining each other and forming fatty cystic chains, H and E ×100
Fig. 8: Liver section of methotrexate-treated rats (moderate 
to severe steatosis) showing fatty cyst chains with chronic 
inflammatory cells infiltration, H and E ×100
Fig. 9: Liver section of methotrexate-treated rats (moderate 
to severe steatosis) showing fatty cyst chains with chronic 
inflammatory cells infiltration, H and E ×100
Fig. 10: Liver section of resatorvid pre-treated rats showing 
moderate steatosis with macrovesicular and microvesicular 
hepatic cell fatty degeneration and fewer numbers of fatty cysts 
chains, H and E ×100
Fig. 11: Liver section of resatorvid pre-treated rats showing 
moderate steatosis with hepatic cell fatty degeneration and fewer 
number of fatty cysts chains. No inflammation observed H and E 
×100
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Fig. 12: Liver section of resatorvid pretreated rats showing 
moderate steatosis with macrovesicular hepatic cells fatty 
degeneration and fewer number of fatty cysts chains. No 
inflammation observed H and E ×100
Fig. 13: Liver section of resatorvid pretreated rats showing 
moderate steatosis with hepatic cell fatty degeneration and fatty 
cysts chains. No inflammation observed H and E ×100
drug [35]. It resulted in haematological and gastrointestinal toxicities even 
when administered in low-dose regimen [36,37], and it is a usual cause 
of hepatocellular injury and death [38,39]. A methotrexate-induced liver 
injury may present as steatosis, cholestasis, fibrosis, cirrhosis, and in rare 
case acute liver failure [11,31,34,40]. In this study, we found that MTX-
treated animals showed moderate to severe steatosis in comparison with 
animals in the control group. Both microvesicular and macrovesicular fatty 
vacuoles that are rejoining and form a fatty cyst (ballooning degeneration), 
pyknosis of chromatin in the nucleus was seen with a peripheralized nuclei 
that result in a shape of a signet ring. Moderate inflammation observed 
in the histological section of treated animals with infiltration of chronic 
inflammatory cells. The histopathological changes we achieved in this study 
are in consistent with the previous studies, which described severe focal 
necrosis accompanied by hepatic granular damage, abnormal hepatocytes 
rearrangement around central vein with shrunken and inflected nuclei, 
infiltration of mononuclear cells, vascular congestion, increased KCs 
activation and proliferated connective tissue in hepatic sections of those 
rats treated with MTX [15,20,21,34,41-43]. Despite, our finding represent 
the moderate-severe patterns of MTX-induced liver injury and thus we 
described milder steatohepatitic changes [11,31,34,39,40].
These changes attributed to MTX increment in both oxidative and 
nitrosative stress, that resulted from liver exposure to high levels 
of MTX-oxidizing metabolites [11,31]. Methotrexate inhibition of 
cytoplasmic de novo synthetic pathways of purines, pyrimidines as well 
as polyamines that leads to diminished hepatic folate reservoir, restrain 
folate entrance to the mitochondria, affect nucleic acid synthesis in 
S-phase and thus render hepatic cell death and further generation 
of FR [9,23,44].  Imbalance in cellular oxidant/antioxidant enzymes, 
which causes decreased availability of cytosolic nicotinamide adenosine 
diphosphate hydrogen (NADPH) that in turn affect the reduced state 
of cellular glutathione, also the decreased the level of superoxide 
dismutase and catalase [20,21,39,42]. These mechanisms will obstruct 
hepatic cholesterol and TG metabolism resulting in fatty infiltration, also 
would increase cellular sensitization to FR leading to stimulation of 
inflammatory response by activating KCs, HSCs, and macrophages (MQ). 
Such scenarios lead to fibrosis, leukocyte accumulation, neutrophils 
secretion of pro-inflammatory enzymes and CKs like inducible 
nitric  oxide  synthase  (iNOS),  Nuclear  factor-κB  (NF-κB)  and  tumour 
necrosis factor-α (TNF-α). This,  in turn, causes more production of FR 
causes sinusoidal congestion, dilation, hepatic fatty vacuolation, focal 
necrosis and portal inflammation which is the typical pattern of drug-
induced steatohepatitis (DISH) produced by FR [20,31,34,40]. 
Liver sections of resatorvid pre-treated rats showed moderate steatosis 
with NAFLD scores of 3, some restoration of macrovesicular and 
microvesicular hepatocytes fatty degeneration, and decrease in number of 
fatty cysts chains, with total reservation of infiltrated inflammatory cells but 
with incomplete ameliorating of the hepatic histological injuries induced by 
MTX. This protective effect is promising but not satisfying. It may indicate 
the requirement of longer treatment courses or coadministration courses. 
Still, it could be explained by resatorvid antagonism of TLR4 activation and 
upregulation caused by intracellular and extracellular damage-associated 
molecular patterns released during oxidative stress [45]. As a selective 
antagonist of TLR4, resatorvid inhibits both TLR4-Myeloid differential88 
(MyD88)-dependent and MyD88-independent signaling pathways which 
induce  inflammatory  immune response and release of CK as TNF-α and 
interleukin-6 [46-48]. This inhibition is rather attributed to the inhibition 
of FR generation resultant from the activation of TLR4-MyD88-dependent 
signaling cascade that stimulates mitogen-activated protein kinase and 
c-Jun phosphorylation which are involved in FR generation [47,49].
CONCLUSION
Resatorvid hepatoprotective effect against MTX-induced injury was 
promising throughout resolving the accompanied inflammation and 
partial restoring histopathological fatty alterations.
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